GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestial Biolabs Ltd (BOM:532871) » Definitions » Debt-to-EBITDA

Celestial Biolabs (BOM:532871) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Celestial Biolabs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Celestial Biolabs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Celestial Biolabs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.00 Mil. Celestial Biolabs's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹-1.28 Mil. Celestial Biolabs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Celestial Biolabs's Debt-to-EBITDA or its related term are showing as below:

BOM:532871' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -85.4   Med: 0.85   Max: 2.38
Current: -45.59

During the past 13 years, the highest Debt-to-EBITDA Ratio of Celestial Biolabs was 2.38. The lowest was -85.40. And the median was 0.85.

BOM:532871's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.36 vs BOM:532871: -45.59

Celestial Biolabs Debt-to-EBITDA Historical Data

The historical data trend for Celestial Biolabs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celestial Biolabs Debt-to-EBITDA Chart

Celestial Biolabs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.12 -2.29 -85.40 -34.13 -22.08

Celestial Biolabs Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -39.30 - -12.96 -

Competitive Comparison of Celestial Biolabs's Debt-to-EBITDA

For the Biotechnology subindustry, Celestial Biolabs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celestial Biolabs's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celestial Biolabs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Celestial Biolabs's Debt-to-EBITDA falls into.



Celestial Biolabs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Celestial Biolabs's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(30.533 + 89.774) / -5.448
=-22.08

Celestial Biolabs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.276
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Celestial Biolabs  (BOM:532871) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Celestial Biolabs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Celestial Biolabs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Celestial Biolabs (BOM:532871) Business Description

Traded in Other Exchanges
N/A
Address
Plot No. 59, Road No 12, TSIIC Tech Park, IDA Nacharam, Hyderabad, TG, IND, 500076
Celestial Biolabs Ltd is an India based biopharmaceutical company. It is engaged in the business activity producing and supplying of the biotechnological products. The company offers herbal, feed supplement and nutraceutical products. The proprietary herbal products of the group include BIOVITA, CADALMIN GAE, CEL-DIGEST, BIOLIV, RHUMACEL, CEL-CLEAR, Trem Plus, O-KOF, BIOPOWER GOLD, BIO-DNORM, DERMACEL, GYNOCEL, HEALTHONE, RELIFIN, and C-KAPS. The organization formulates and manufactures Ayurvedic proprietary products for the Indian market.

Celestial Biolabs (BOM:532871) Headlines

No Headlines